Onno van de Stolpe (1959) obtained an MSc degree from the Agricultural University in Wageningen (WUR) in the Netherlands. He then started his career as Manager Business Development at MOGEN in Leiden, before joining the Netherlands Foreign Investment Agency in California. When he returned to The Netherlands in 1995, Onno set up the European operations for Molecular Probes in Leiden.  Three years later he joined Crucell to set up a new genomics division for the company. In 1999, this division was spun out and Galapagos was incorporated. Over a period of 24 years, he grew Galapagos as its CEO to one of the largest biotech companies in Europe with over 1300 employees and brought Jyseleca, a drug for inflammatory disease, to the market. In 2022 he left the company to pursue new interests. For many years Onno has taken an interest in African wildlife, and has been supporting African Parks for five years before joining the Dutch Board in 2022.